US20220033387A1 - 2'-halogenated-4'-thio-2'-deoxy-5-azacytidine analogs and use thereof - Google Patents

2'-halogenated-4'-thio-2'-deoxy-5-azacytidine analogs and use thereof Download PDF

Info

Publication number
US20220033387A1
US20220033387A1 US17/278,625 US201917278625A US2022033387A1 US 20220033387 A1 US20220033387 A1 US 20220033387A1 US 201917278625 A US201917278625 A US 201917278625A US 2022033387 A1 US2022033387 A1 US 2022033387A1
Authority
US
United States
Prior art keywords
compound
effective amount
administering
subject
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US17/278,625
Other languages
English (en)
Inventor
Joel Morris
Donn G. Wishka
Omar Diego Lopez
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
US Department of Health and Human Services
Original Assignee
US Department of Health and Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by US Department of Health and Human Services filed Critical US Department of Health and Human Services
Priority to US17/278,625 priority Critical patent/US20220033387A1/en
Assigned to THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES reassignment THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: LOPEZ, Omar Diego, MORRIS, JOEL, WISHKA, DONN G.
Publication of US20220033387A1 publication Critical patent/US20220033387A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/12—Triazine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Definitions

  • This disclosure concerns halogenated analogs of 5-aza-2′-deoxycytidine, such as halogenated analogs of 5-aza-4′-thio-2′-deoxycytidine (5-aza-T-dCyd), and methods of using the halogenated analogs.
  • Halogenated analogs of 5-aza-2′-deoxycytidine and methods of using the halogenated analogs are disclosed.
  • the compounds have a structure according to formula Ia, or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof:
  • X is F; or (ii) Y is hydrogen; or (iii) each R is hydrogen; or (iv) R a is hydrogen; or (v) any combination of (i), (ii), (iii), and (iv).
  • the compound has a structure according to any one of formulas IIa-Va, or any combination thereof:
  • X may be F
  • Y may be H or F
  • each R may be H
  • R a may be H.
  • the compound is:
  • a pharmaceutical composition may include at least one of the disclosed compounds and a pharmaceutically acceptable carrier.
  • the pharmaceutical composition is formulated for intravenous, oral, intraperitoneal, subcutaneous, rectal, or buccal administration.
  • a method of inhibiting a neoplasia includes contacting neoplastic cells with an effective amount of a compound as disclosed herein. In some embodiments, contacting the neoplastic cells with the effective amount of the compound reduces proliferation of the neoplastic cells.
  • contacting the neoplastic cells with the effective amount of the compound may include administering a therapeutically effective amount of the compound to a subject having or suspected of having a disease characterized at least in part by presence of neoplastic cells, for example, a cancer.
  • the cancer is a cancer of the kidney, bladder, breast, colon, endometrium, skin, blood, pancreas, prostate, bone, liver, lung, esophagus, or central nervous system.
  • administering the therapeutically effective amount of the compound to the subject may reduce a sign or symptom of the disease.
  • FIG. 1 is an exemplary synthesis scheme for 4-amino-1-((2R,3S,4S,5R)-fluoro-4-hydroxy-5-(hyoxymethyl)tettahydrothiophen-2-yl)-1,3,5-triazin-2(1H)-one (Compound 1).
  • FIGS. 3A and 3B show GI50 (drug concentration resulting in a 50% reduction in net protein increase) data for Compound 1 and 5-aza-T-dCyd, respectively, against leukemia cell lines.
  • FIGS. 4A and 4B show GI50 data for Compound 1 and 5-aza-T-dCyd. respectively, against central nervous system (CNS) cancer cell lines.
  • FIGS. 5A and 5B show GI50 data for Compound 1 and 5-aza-T-dCyd, respectively, against renal cancer cell lines.
  • FIGS. 6A and 6B show GI50 data for Compound 1 and 5-aza-T-dCyd, respectively, against non-small cell lung cancer cell lines.
  • FIGS. 7A and 7B show GI50 data for Compound 1 and 5-aza-T-dCyd, respectively, against melanoma cell lines.
  • FIGS. 8A and 8B show GI50 data for Compound 1 and 5-aza-T-dCyd, respectively, against prostate cancer cell lines.
  • FIGS. 9A and 9B show GI50 data for Compound 1 and 5-T-dCyd, respectively, against colon cancer cell lines.
  • FIGS. 10A and 10B show GI50 data for Compound 1 and 5-aza-T-dCyd, respectively against ovarian cancer cell lines.
  • FIGS. 11A and 11B show GI50 data for Compound 1 and 5-aza-T-dCyd, respectively, against breast cancer cell lines.
  • FIGS. 12A and 12B show HCT-116 human colon carcinoma xenograft tumor volume and mouse body weight, respectively, over time in mice administered 10 mg/kg Compound 1 (F-aza-TdCyd) intraperitoneally QDx5, rest and repeat for 4 cycles; 400 mg/kg Compound 1 intraperitoneally Q7Dx3; 240 mg/kg F-TdCyd intravenously Q7Dx4; 1.5 mg/kg 5-aza-T-dCyd intraperitoneally QDx5, rest and repeat for 4 cycles; or 150 mg/kg gemcitabine intraperitoneally Q7Dx3.
  • Compound 1 F-aza-TdCyd
  • FIGS. 12A and 12B show HCT-116 human colon carcinoma xenograft tumor volume and mouse body weight, respectively, over time in mice administered 10 mg/kg Compound 1 (F-aza-TdCyd) intraperitoneally QDx5, rest and repeat for 4 cycles; 400 mg/kg Compound 1 intraperitoneally Q7Dx3;
  • FIGS. 13A and 13B show BL0382 human bladder carcinoma xenograft tumor volume and mouse body weight, respectively, over time in mice administered 8 mg/kg Compound 1 (F-aza-TdCyd) intraperitoneally QDx5, rest for 3 cycles; 250 mg/kg Compound 1 intraperitoneally Q7Dx3; 200 mg/kg F-TdCyd intravenously Q7Dx3; 1.5 mg/kg 5-aza-T-dCyd intraperitoneally QDx5, rest and repeat for 3 cycles; 150 mg/kg gemcitabine intraperitoneally Q7Dx3; or 8 mg/kg Compound 1 orally QDx5, rest for 3 cycles.
  • Compound 1 F-aza-TdCyd
  • FIGS. 14A and 14B show OVCAR3 human ovarian carcinoma xenograft tumor volume and mouse body weight, respectively, over time in mice administered 8 mg/kg Compound 1 (F-aza-TdCyd) intraperitoneally QDx5, rest for 3 cycles; 250 mg/kg Compound 1 intraperitoneally Q7Dx3; 200 mg/kg F-TdCyd intravenously Q7Dx3; 1.5 mg/kg 5-aza-T-dCyd intraperitoneally QDx5, rest and repeat for 3 cycles; 150 mg/kg gemcitabine intraperitoneally Q7Dx3; or 8 mg/kg Compound 1 orally QDx5, rest for 3 cycles.
  • Compound 1 F-aza-TdCyd
  • FIGS. 15A and 15B show NCI-H23 NSCLC human lung carcinoma xenograft tumor volume and mouse body weight, respectively, over time in mice administered 10 mg/kg Compound 1 (F-aza-TdCyd) intraperitoneally QDx5, rest for 3 cycles; 80 mg/kg Compound 1 orally QDx5, rest for 3 cycles; 400 mg/kg Compound 1 intraperitoneally Q7Dx3; 240 mg/kg F-TdCyd intravenously Q7Dx3; 1.5 mg/kg 5-aza-T-dCyd intraperitoneally QDx5, rest for 3 cycles; or 150 mg/kg gemcitabine intraperitoneally Q7Dx3.
  • Compound 1 F-aza-TdCyd
  • FIGS. 16A and 16B show HL-60 human leukemia xenograft tumor volume and mouse body weight, respectively, over time mice administered 10 mg/kg Compound 1 (F-aza-TdCyd) intraperitoneally QDx5, rest for 3 cycles; 400 mg/kg Compound 1 intraperitoneally Q7Dx3; 240 mg/kg F-TdCyd intravenously Q7Dx3; 1.5 mg/kg 5-aza-T-dCyd intraperitoneally QDx5, rest for 3 cycles; or 150 mg/kg gemcitabine intraperitoneally Q7Dx3.
  • Compound 1 F-aza-TdCyd
  • FIGS. 16A and 16B show HL-60 human leukemia xenograft tumor volume and mouse body weight, respectively, over time mice administered 10 mg/kg Compound 1 (F-aza-TdCyd) intraperitoneally QDx5, rest for 3 cycles; 400 mg/kg Compound 1 intraperitoneally Q7Dx3; 240 mg/kg F-T
  • Halogenated analogs of 5-aza-2′-deoxycytidine and methods of using the halogenated analogs are disclosed.
  • the compounds are halogenated analogs of 5-aza-4′-thio-2′-deoxycytidine (5-aza-T-dCyd).
  • the disclosed compounds may be useful for treating diseases characterized at least in part by the presence of neoplastic cells, such as cancers.
  • Some embodiments of the disclosed halogenated analogs may be more efficacious with respect to treating certain cancers, than the corresponding non-halogenated aza compounds and/or corresponding halogenated, but non-aza analogs.
  • Active agent A drug, medicament, pharmaceutical, therapeutic agent, nutraceutical, or other compound administered to a subject to effect a change, such as treatment, amelioration, or prevention of a disease or disorder or at least one symptom associated therewith.
  • the term active agent also includes biological active agents such as proteins, antibodies, antibody fragments, peptides, oligonucleotides, vaccines, and various derivatives of such materials.
  • Alkyl A hydrocarbon group having a saturated carbon chain.
  • the chain may be cyclic, branched or unbranched. Examples, without limitation, of alkyl groups include methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, nonyl and decyl.
  • Alkoxy A radical (or substituent) having the structure —OR, where R is a substituted or unsubstituted alkyl. Methoxy (—OCH 3 ) is an exemplary alkoxy group. In a substituted alkoxy, R is alkyl substituted with a non-interfering substituent.
  • Anomer An epimer (an isomer having a different configuration at just one chiral carbon) occurring in cyclic saccharides.
  • Co-administration refers to administration of a compound disclosed herein with at least one other active agent within the same general time period, and does not require administration at the same exact moment in time (although co-administration is inclusive of administering at the same exact moment in time). Thus, co-administration may be on the same day or on different days, or in the same week or in different weeks.
  • Effective amount or therapeutically effective amount An amount sufficient to provide a beneficial, or therapeutic, effect to a subject or a given percentage of subjects.
  • Inhibit As used herein, the term “inhibit” means to reduce or prevent.
  • Neoplasia/neoplasm/neoplastic A neoplasia is an abnormal growth of tissue or blood cells. The abnormal growth may form a solid mass or tumor.
  • a neoplasm can be benign, in situ (e.g., a non-invasive cancer or precancerous neoplasm) or malignant (e.g., a cancer).
  • parenteral formulations usually comprise injectable fluids that include pharmaceutically and physiologically acceptable fluids such as water, physiological saline, balanced salt solutions, aqueous dextrose, glycerol or the like as a vehicle.
  • the pharmaceutically acceptable carrier may be sterile to be suitable for administration to a subject (for example, by parenteral, intramuscular, or subcutaneous injection).
  • pharmaceutical compositions to be administered can contain minor amounts of non-toxic auxiliary substances, such as wetting or emulsifying agents, preservatives, and pH buffering agents and the like, for example sodium acetate or sorbitan monolaurate.
  • a biologically compatible salt of a disclosed cyanine fluorophores which salts are derived from a variety of organic and inorganic counter ions well known in the art and include, by way of example only, sodium, potassium, calcium, magnesium, ammonium, tetraalkylammonium, and the like; and when the molecule contains a basic functionality, salts of organic or inorganic acids, such as hydrochloride, hydrobromide, tartrate, mesylate, acetate, maleate, oxalate, and the like.
  • Pharmaceutically acceptable acid addition salts are those salts that retain the biological effectiveness of the free bases while formed by acid partners that are not biologically or otherwise undesirable, e.g., inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, and the like, as well as organic acids such as acetic acid, trifluoroacetic acid, propionic acid, glycolic acid, pyruvic acid, oxalic acid, maleic acid, malonic acid, succinic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, salicylic acid and the like.
  • inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, and the like
  • organic acids such as acetic acid, triflu
  • Pharmaceutically acceptable base addition salts include those derived from inorganic bases such as sodium, potassium, lithium, ammonium, calcium, magnesium, iron, zinc, copper, manganese, aluminum salts and the like.
  • Exemplary salts are the ammonium, potassium, sodium, calcium, and magnesium salts.
  • Salts derived from pharmaceutically acceptable organic non-toxic bases include, but are not limited to, salts of primary, secondary, and tertiary amines, substituted amines including naturally occurring substituted amines, cyclic amines and basic ion exchange resins, such as isopropylamine, trimethylamine, diethylamine, triethylamine, tripropylamine, ethanolamine, 2-dimethylaminoethanol, 2-diethylaminoethanol, dicyclohexylamine, lysine, arginine, histidine, caffeine, procaine, hydrabamine, choline, betaine, ethylenediamine, glucosamine, methylglucamine, theobromine, purines, piperazine, piperidine, N-ethylpiperidine, polyamine resins, and the like.
  • salts of primary, secondary, and tertiary amines substituted amines including naturally occurring substituted amines, cyclic amines
  • organic bases are isopropylamine, diethylamine, ethanolamine, trimethylamine, dicyclohexylamine, choline, and caffeine. (See, for example, S. M. Berge, et al., “Pharmaceutical Salts,” J. Pharm. Sci., 1977; 66:1-19, which is incorporated herein by reference.)
  • Stereochemistry The three-dimensional spatial configuration of a molecule.
  • Stereoisomer Isomers that have the same molecular formula and sequence of bonded atoms, but which differ only in the three-dimensional orientation of the atoms in space.
  • Subject An animal or human subjected to a treatment, observation or experiment.
  • Tautomers Constitutional isomers of organic compounds that differ only in the position of the protons and electrons, and are interconvertible by migration of a hydrogen atom. Tautomers ordinarily exist together in equilibrium.
  • Treat/treatment means to inhibit (reduce or prevent) at least one sign or symptom associated with a condition, i.e., a disorder or disease.
  • treating may mean reducing or preventing tumor growth, reducing a tumor volume, and/or reducing or preventing tumor metastasis.
  • Treatment may, for example, produce a reduction in severity of some or all clinical symptoms of the tumor, a slower progression of the tumor (for example by prolonging the life of a subject having the tumor), a reduction in the number of tumor reoccurrence, an improvement in the overall health or well-being of the subject, or by other parameters well known in the art that are specific to the particular disorder or disease.
  • X is halo (F, Cl, Br, or I)
  • Y is hydrogen, halo (F, Cl, Br, or I), or deuterium
  • Z is S or O
  • each R independently is hydrogen or deuterium
  • R a is hydrogen, deuterium, alkyl (e.g., C 1-5 or C 1-3 alkyl, such as methyl, ethyl, n-propyl, or isopropyl) alkoxy, amino, or halo.
  • Z is S.
  • X may be F.
  • Y may be hydrogen or F.
  • each R may be hydrogen.
  • R a may be hydrogen.
  • the compound is a halogenated analog of 5-aza-4′-thio-2′-deoxycitidine (5-aza-T-dCyd) and has a structure according to general formula Ia where X, Y, R, and R a are as defined above:
  • halogenated analogs may have a stereochemistry according to any one of formulas II-V or any combination thereof, where X, Y, Z, R, and R a are as defined above:
  • Z is S, and the compound has a structure according to any one of formulas IIa-Va, or any combination thereof:
  • the compound is a 0-anomer, i.e., a compound according to formula II, IIa, III, or Ma.
  • Exemplary compounds include, but are not limited to:
  • the compound is:
  • the compound is:
  • compositions comprising at least one compound as disclosed herein.
  • Some embodiments of the pharmaceutical compositions include a pharmaceutically acceptable carrier and at least one compound.
  • the pharmaceutical compositions can also include one or more additional active ingredients such as anti-cancer agents, anti-inflammatory agents, antiviral agents, antimicrobial agents, anesthetics, and the like.
  • additional active ingredients such as anti-cancer agents, anti-inflammatory agents, antiviral agents, antimicrobial agents, anesthetics, and the like.
  • the pharmaceutically acceptable carriers useful for these formulations are conventional. Remington's Pharmaceutical Sciences , by E. W. Martin, Mack Publishing Co., Easton, Pa., 19 th Edition (1995), for example, describes compositions and formulations suitable for pharmaceutical delivery of the compounds herein disclosed.
  • the compounds according to Formula I disclosed herein can be administered to subjects by a variety of routes, including by parenteral, oral, or rectal routes.
  • Parenteral routes include, but are not limited to, intravenous, intraperitoneal, subcutaneous, buccal, and sublingual routes.
  • the compounds can be administered ex vivo by direct exposure to cells, tissues or organs originating from a subject. Ex vivo administration may be useful, for example, to determine whether a cell (e.g., a cancer cell) is responsive to administration of the compound.
  • the pharmaceutical compositions may be in a dosage unit form such as an injectable fluid, an oral delivery fluid (e.g., a solution or suspension), a nasal delivery fluid (e.g., for delivery as an aerosol or vapor), a semisolid form (e.g., a topical cream), or a solid form such as powder, pill, tablet, or capsule forms.
  • a dosage unit form such as an injectable fluid, an oral delivery fluid (e.g., a solution or suspension), a nasal delivery fluid (e.g., for delivery as an aerosol or vapor), a semisolid form (e.g., a topical cream), or a solid form such as powder, pill, tablet, or capsule forms.
  • parenteral formulations usually contain injectable fluids that include pharmaceutically and physiologically acceptable fluids such as water, physiological saline, balanced salt solutions, aqueous dextrose, glycerol or the like as a vehicle.
  • injectable fluids such as water, physiological saline, balanced salt solutions, aqueous dextrose, glycerol or the like as a vehicle.
  • physiologically acceptable fluids such as water, physiological saline, balanced salt solutions, aqueous dextrose, glycerol or the like
  • solid compositions for example, powder, pill, tablet, or capsule forms
  • conventional non-toxic solid carriers can include, for example, pharmaceutical grades of mannitol, lactose, starch, or magnesium stearate.
  • compositions to be administered can contain minor amounts of non-toxic auxiliary substances, such as wetting or emulsifying agents, preservatives, and pH buffering agents and the like, for example sodium acetate or sorbitan monolaurate.
  • non-toxic auxiliary substances such as wetting or emulsifying agents, preservatives, and pH buffering agents and the like, for example sodium acetate or sorbitan monolaurate.
  • the compounds can be combined with various pharmaceutically acceptable additives, as well as a base or vehicle for dispersion of the compound.
  • Desired additives include, but are not limited to, pH control agents, such as arginine, sodium hydroxide, glycine, hydrochloric acid, citric acid, and the like.
  • isotonizing agents for example, sodium chloride, mannitol, sorbitol
  • adsorption inhibitors for example, Tween® 80 polyethylene sorbitol ester or Miglyol® 812 triglycerides
  • solubility enhancing agents for example, cyclodextrins and derivatives thereof
  • stabilizers for example, serum albumin
  • reducing agents for example, glutathione
  • Adjuvants such as aluminum hydroxide (for example, Amphogel, Wyeth Laboratories, Madison, N.J.), Freund's adjuvant, MPLTM (3-O-deacylated monophosphoryl lipid A; Corixa, Hamilton, Ind.) and IL-12 (Genetics Institute, Cambridge, Mass.), among many other suitable adjuvants well known in the art, can be included in the compositions.
  • the tonicity of the formulation as measured with reference to the tonicity of 0.9% (w/v) physiological saline solution taken as unity, is typically adjusted to a value at which no substantial, irreversible tissue damage will be induced at the site of administration.
  • the tonicity of the solution is adjusted to a value of about 0.3 to about 3.0, such as about 0.5 to about 2.0, or about 0.8 to about 1.7.
  • the compounds can be dispersed in a base or vehicle, which can include a hydrophilic compound having a capacity to disperse the compound, and any desired additives.
  • the base can be selected from a wide range of suitable compounds, including but not limited to, copolymers of polycarboxylic acids or salts thereof, carboxylic anhydrides (for example, maleic anhydride) with other monomers (for example, methyl (meth)acrylate, acrylic acid and the like), hydrophilic vinyl polymers, such as polyvinyl acetate, polyvinyl alcohol, polyvinylpyrrolidone, cellulose derivatives, such as hydroxymethylcellulose, hydroxypropylcellulose and the like, and natural polymers, such as chitosan, collagen, sodium alginate, gelatin, hyaluronic acid, and nontoxic metal salts thereof.
  • a biodegradable polymer is selected as a base or vehicle, for example, polylactic acid, poly(lactic acid-glycolic acid) copolymer, polyhydroxybutyric acid, poly(hydroxybutyric acid-glycolic acid) copolymer and mixtures thereof.
  • synthetic fatty acid esters such as polyglycerin fatty acid esters, sucrose fatty acid esters and the like can be employed as vehicles.
  • Hydrophilic polymers and other vehicles can be used alone or in combination, and enhanced structural integrity can be imparted to the vehicle by partial crystallization, ionic bonding, cross-linking and the like.
  • the vehicle can be provided in a variety of forms, including fluid or viscous solutions, gels, pastes, powders, microspheres and films for direct application to a mucosal surface.
  • the compounds can be combined with the base or vehicle according to a variety of methods, and release of the compounds can be by diffusion, disintegration of the vehicle, or associated formation of water channels.
  • the compound is dispersed in microcapsules (microspheres) or nanocapsules (nanospheres) prepared from a suitable polymer, for example, isobutyl 2-cyanoacrylate (see, for example, Michael et al., J. Pharmacy Pharmacol. 43:1-5, 1991), and dispersed in a biocompatible dispersing medium, which yields sustained delivery and biological activity over a protracted time.
  • compositions of the disclosure can alternatively contain, as pharmaceutically acceptable vehicles, substances as required to approximate physiological conditions, such as pH adjusting and buffering agents, tonicity adjusting agents, wetting agents and the like, for example, sodium acetate, sodium lactate, sodium chloride, potassium chloride, calcium chloride, sorbitan monolaurate, and triethanolamine oleate.
  • pharmaceutically acceptable vehicles include, for example, pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium saccharin, talcum, cellulose, glucose, sucrose, magnesium carbonate, and the like.
  • compositions for administering the compounds can also be formulated as a solution, microemulsion, or other ordered structure suitable for high concentration of active ingredients.
  • the vehicle can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (for example, glycerol, propylene glycol, liquid polyethylene glycol, and the like), and suitable mixtures thereof.
  • polyol for example, glycerol, propylene glycol, liquid polyethylene glycol, and the like
  • suitable mixtures thereof for example, water, ethanol, polyol (for example, glycerol, propylene glycol, liquid polyethylene glycol, and the like), and suitable mixtures thereof.
  • Proper fluidity for solutions can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of a desired particle size in the case of dispersible formulations, and by the use of surfactants.
  • isotonic agents for example, sugars, polyalcohols, such as mannitol and sorbitol, or sodium chloride in the composition.
  • Prolonged absorption of the compound can be brought about by including in the composition an agent which delays absorption, for example, monostearate salts and gelatin.
  • the compounds can be administered in a time release formulation, for example in a composition which includes a slow release polymer.
  • a composition which includes a slow release polymer can be prepared with vehicles that will protect against rapid release, for example a controlled release vehicle such as a polymer, microencapsulated delivery system or bioadhesive gel. Prolonged delivery in various compositions of the disclosure can be brought about by including in the composition agents that delay absorption, for example, aluminum monostearate hydrogels and gelatin.
  • controlled release binders suitable for use in accordance with the disclosure include any biocompatible controlled release material which is inert to the active compound and which is capable of incorporating the compound and/or other biologically active agent. Numerous such materials are known in the art.
  • Useful controlled-release binders are materials that are metabolized slowly under physiological conditions following their delivery (for example, at a mucosal surface, or in the presence of bodily fluids).
  • Appropriate binders include, but are not limited to, biocompatible polymers and copolymers well known in the art for use in sustained release formulations.
  • biocompatible compounds are non-toxic and inert to surrounding tissues, and do not trigger significant adverse side effects, such as nasal irritation, immune response, inflammation, or the like. They are metabolized into metabolic products that are also biocompatible and easily eliminated from the body.
  • Exemplary polymeric materials for use in the present disclosure include, but are not limited to, polymeric matrices derived from copolymeric and homopolymeric polyesters having hydrolyzable ester linkages. A number of these are known in the art to be biodegradable and to lead to degradation products having no or low toxicity.
  • Exemplary polymers include polyglycolic acids and polylactic acids, poly(DL-lactic acid-co-glycolic acid), poly(D-lactic acid-co-glycolic acid), and poly(L-lactic acid-co-glycolic acid).
  • biodegradable or bioerodable polymers include, but are not limited to, such polymers as poly(epsilon-caprolactone), poly(epsilon-caprolactone-CO-lactic acid), poly(epsilon.-caprolactone-CO-glycolic acid), poly(beta-hydroxy butyric acid), poly(alkyl-2-cyanoacrilate), hydrogels, such as poly(hydroxyethyl methacrylate), polyamides, poly(amino acids) (for example, L-leucine, glutamic acid, L-aspartic acid and the like), poly(ester urea), poly(2-hydroxyethyl DL-aspartamide), polyacetal polymers, polyorthoesters, polycarbonate, polymaleamides, polysaccharides, and copolymers thereof.
  • polymers such as polymers as poly(epsilon-caprolactone), poly(epsilon-caprolactone-CO-lactic acid
  • compositions of the disclosure typically are sterile and stable under conditions of manufacture, storage and use.
  • Sterile solutions can be prepared by incorporating the compound in the required amount in an appropriate solvent with one or a combination of ingredients enumerated herein, as required, followed by filtered sterilization.
  • dispersions are prepared by incorporating the compound and/or other biologically active agent into a sterile vehicle that contains a basic dispersion medium and the required other ingredients from those enumerated herein.
  • methods of preparation include vacuum drying and freeze-drying which yields a powder of the compound plus any additional desired ingredient from a previously sterile-filtered solution thereof.
  • the prevention of the action of microorganisms can be accomplished by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, sorbic acid, thimerosal, and the like.
  • the compounds can be delivered to a subject in a manner consistent with conventional methodologies associated with management of the disorder for which treatment or prevention is sought.
  • a prophylactically or therapeutically effective amount of the compound(s) is administered to a subject in need of such treatment for a time and under conditions sufficient to inhibit and/or treat a disease (e.g., a cancer) or one or more symptom(s) thereof.
  • the compounds can be administered to the subject by the oral route or in a single bolus delivery, via continuous delivery (for example, continuous transdermal, mucosal or intravenous delivery) over an extended time period, or in a repeated administration protocol (for example, by an hourly, daily or weekly, repeated administration protocol).
  • the therapeutically effective dosages of the compounds can be provided as repeated doses within a prolonged prophylaxis or treatment regimen that will yield clinically significant results to alleviate one or more symptoms or detectable conditions associated with a targeted condition as set forth herein. Determination of effective dosages in this context is typically based on animal model studies followed up by human clinical trials and is guided by administration protocols that significantly reduce the occurrence or severity of targeted disease symptoms or conditions in the subject. Suitable models in this regard include, for example, murine, rat, avian, porcine, feline, non-human primate, and other accepted animal model subjects known in the art.
  • a compound according to formula I, or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof inhibits a neoplasia when neoplastic cells are contacted with an effective amount of the compound.
  • Inhibition of a neoplasia includes reducing a sign or symptom associated with the neoplasia, such as a rate of growth or proliferation of neoplastic cells relative to a rate of proliferation in the absence of the compound.
  • inhibiting the neoplasia may reduce or prevent tumor growth, reduce tumor volume, and/or reduce metastasis of the solid tumor.
  • Neoplasias may be benign, in situ/precancerous, or malignant.
  • the neoplasia is malignant—that is, a cancer—and contacting the cancer cells with an effective amount of the compound according to formula I reduces or prevents proliferation of the cancer cells.
  • Cancers that may be inhibited or treated by administration of the disclosed compounds include, but are not limited to, cancers of the kidney (renal cell), bladder, breast (male and female), colon, endometrium, lung (including bronchus), skin (including melanoma), blood (e.g., leukemia, lymphoma (for example, non-Hodgkin's lymphoma), myeloma), pancreas, prostate, bone, liver, lung, esophagus, and central nervous system cancers.
  • neoplastic cells with the compound according to formula I may be performed in vitro, in vivo, or ex vivo.
  • the cells may be contacted in vitro (for example, in a cell culture) or ex vivo (for example, in a biological sample obtained from a subject) to determine whether the compound reduces or prevents cellular growth and/or proliferation.
  • contacting neoplastic cells with the effective amount of the compound comprises administering a therapeutically effective amount of the compound to a subject having or suspected of having a disease characterized at least in part by presence of neoplastic cells.
  • the subject may be a mammal, such as a human or a non-human mammal (for example, a dog, cat, horse, rabbit, or the like).
  • the neoplastic cells are malignant and the disease is a cancer.
  • administering the therapeutically effective amount of the compound to the subject may reduce a sign or symptom of the disease.
  • the sign or symptom is a solid tumor and administering the therapeutically effective amount of the compound to the subject reduces growth of the solid tumor, reduces a volume of the solid tumor, reduces metastasis of the solid tumor, or any combination thereof.
  • the sign or symptom may be an abnormal complete blood count and administering the therapeutically effective amount of the compound to the subject partially or fully normalizes the complete blood count.
  • neoplastic cells include, but are not limited to, coughing, shortness of breath, coughing up blood, swelling, pain, fever, chills, frequent infections, itchy skin or rash, loss of appetite, nausea, night sweats, persistent weakness, fatigue, shortness of breath, bloating, changes in bowel or bladder habits, constipation, diarrhea, bloody stools, rectal bleeding, jaundice, abnormal vaginal bleeding, difficulty swallowing, voice changes, mouth sores, dry mouth, flu-like symptoms, headaches, easy bruising or bleeding, enlarged lymph nodes, and changes in appearance of a mole.
  • Administering the therapeutically effective amount of the compound may comprise administering a pharmaceutical composition comprising the therapeutically effective amount of the compound to the subject.
  • Administration may be by any suitable route including, but not limited to, intravenous, oral, intraperitoneal, subcutaneous, rectal, or buccal administration.
  • the actual dosages of the compounds will vary according to factors such as the disease indication and particular status of the subject (for example, the subject's age, size, fitness, extent of symptoms, susceptibility factors, and the like), time and route of administration, other drugs or treatments being administered concurrently, as well as the specific pharmacology of the agent for eliciting the desired activity or biological response in the subject. Dosage regimens can be adjusted to provide an optimum prophylactic or therapeutic response. A therapeutically effective amount is also one in which any toxic or detrimental side effects of the compound is outweighed in clinical terms by therapeutically beneficial effects.
  • effective dosages can be determined using in vitro models. Using such models, only ordinary calculations and adjustments are required to determine an appropriate concentration and dose to administer a therapeutically effective amount of the compound (for example, amounts that are effective to elicit a desired immune response or alleviate one or more symptoms of a targeted disease).
  • an effective amount or effective dose of the compounds may simply inhibit or enhance one or more selected biological activities correlated with a disease or condition, as set forth herein, for either therapeutic or diagnostic purposes.
  • a non-limiting range for a therapeutically effective amount of a compound according to formula I within the methods and formulations of the disclosure is from 0.0001 grams to 100 grams for an adult human, such as from 0.001 grams to 50 grams, 0.01 grams to 25 grams, or 0.1 grams to 10 grams.
  • the therapeutically effective amount is within a range of from 0.001 mg/kg body weight to 100 mg/kg body weight, such as 0.01 mg/kg body weight to 20 mg/kg body weight, 0.01 mg/kg body weight to 10 mg/kg body weight 0.05 mg/kg to 5 mg/kg body weight, or 0.1 mg/kg to 2 mg/kg body weight.
  • the therapeutically effective amount may be administered in a single dose or split into two or more doses administered over time.
  • the therapeutically effective amount of the compound, or a pharmaceutical composition comprising the compound is administered to a subject in a dosing regimen of once, twice, or three times daily.
  • the dosing regimen may include dosing holidays of 1-14 days.
  • Dosage can be varied by the attending clinician to maintain a desired concentration at a target site (for example, systemic circulation). Higher or lower concentrations can be selected based on the mode of delivery, for example, oral delivery versus intravenous or subcutaneous delivery. Dosage can also be adjusted based on the release rate of the administered formulation, for example, of sustained release oral versus injected particulate or rectal suppository, and so forth.
  • a second active agent may be co-administered with the compound.
  • the compound and the second active agent may be administered either separately or together in a single composition.
  • the second active agent may be administered by the same route or a different route.
  • the compound and the second agent may be administered concurrently or at separate times. Separate administration may be performed in any sequence. If administered concurrently, the compound and the second active agent may be combined in a single pharmaceutical composition or may be administered concurrently as two pharmaceutical compositions.
  • the second active agent may be, for example, an anti-cancer agent, an anti-inflammatory agent, an antimicrobial agent, an antiviral agent, an anesthetic agent, or the like.
  • Illustrative anti-cancer agents include, but are not limited to, abiraterone, actinomycin D, altretamine, amifostine, anastrozole, asparaginase, bexarotene, bicalutamide, bleomycin, buserelin, busulfan, carboplatin, carmustine, chlorambucil cisplatin, cladribine, clodronate, combretastatin A4, cyclophosphamide, cyproterone, cytarabine, dacarbazine, daunorubicin, degarelix, diethylstilbestrol, docetaxel, doxorubicin, duocarmycin DM, epirubicin, ethinyl estradiol, etoposide, exemestane, 5-fluorouracil, fludarabine, flutamide, folinic acid, fulvestrant, gemcitabine, goserelin, i
  • FIG. 1 is an exemplary synthesis scheme for 4-amino-1-((2R,3S,4S,5R)-3-fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrothiophen-2-yl)-1,3,5-triazin-2(1H)-one (Scheme 1).
  • FIG. 2 is an exemplary synthesis scheme for precursor 4-oxyloxyphenylmethanethiol (Scheme 2).
  • the crude bromide was dissolved in DMF (600 mL) in a 3000 mL one-neck round-bottom flask under ambient atmosphere.
  • the solution was treated with triethylamine (317 mL, 2274 mmol) and water (205 mL, 1.14E+04 mmol) and the reaction was stirred at room temperature.
  • the reaction showed an exotherm from 23 to 37° C. upon addition of water/triethylamine mixture.
  • the reaction was stirred for 1 h and then it was diluted with 2400 mL ethyl acetate. After stirring vigorously with 1200 mL 50% saturated sodium chloride, the layers were separated, and the organic layer was washed with 3 ⁇ 500 mL 50% saturated sodium chloride.
  • the oil was diluted with hexane, loaded onto a 125 G RediSep® Rf column (Teledyne ISCO) and was eluted over a 340 G UltraSil SNAP cartridge (Biotage, Charlotte, N.C.) with a 0-20% ethyl acetate/hexane gradient into 27 mL fractions on a Biotage® system. Fractions 28-100 were combined and concentrated to afford 85 g (62%) of the title compound (4) as a golden oil.
  • the paste was slurried with 900 mL 2:1 hexane/tBuOMe (methyl tert-butyl ether) and the insoluble material was removed by filtration. The filtrate was concentrated in vacuo to give 48 g a crude yellow oil.
  • the crude material was dissolved in hexane with a small amount of dichloromethane, was loaded onto a 100 G UltraSil SNAP cartridge and was eluted over a 120 g Zip® Sphere cartridge (Biotage, Charlotte, N.C.) with a 0-20% ethyl acetate/hexane gradient on a Biotage® system. Fractions 4-21 were combined and concentrated to afford 21.70 g (80%) of the title compound (5) as a yellow oil.
  • the suspension was treated dropwise with 2,6-lutidine (2.74 mL, 23.49 mmol) in 35 mL dichloromethane.
  • the heavy suspension gradually achieved near homogeneity within 15 minutes of the lutidine addition.
  • Stirring was continued overnight at room temperature for a total of 23 hours.
  • the reaction was neutralized with citric acid (4.51 g, 23.49 mmol) in water (52 mL), the mixture was diluted with 1 L dichloromethane, and the layers were separated. The organic layer was washed with 1 ⁇ 250 mL 1:115% aqueous citric acid and saturated sodium chloride.
  • the reaction was diluted with 1,000 mL ethyl acetate and extracted with 1 ⁇ 500 mL 50% saturated sodium chloride followed by 3 ⁇ 150 mL 50% saturated sodium chloride. The organic layer was dried over anhydrous magnesium sulfate and concentrated in vacuo to a colorless oil.
  • the crude material was dissolved in a minimum amount of hexane, was loaded onto a 340 G UltraSil SNAP cartridge, and was eluted with a 0-15% ethyl acetate/hexane gradient into 27 mL fractions on a Biotage® system. Fractions 27-66 were combined and concentrated to afford 36.7 g (95%) of the title compound (11) as a colorless oil.
  • HMDS (21.97 mL, 105 mmol) was added to azacytosine (2.91 g, 26.2 mmol) and ammonium sulfate (0.115 g, 0.873 mmol), and the resulting mixture was stirred at 130° C. for 20 h. Excess HMDS was removed under reduced pressure and the remaining residue was suspended in 1,2-dichloroethane (50 mL).
  • the layers were separated and the organic layer was dried over anhydrous magnesium sulfate.
  • the solution of intermediate bromide was added to the suspension of silylated azacytosine in a single portion and the white suspension was warmed to 84° C. The suspension became a light slurry as the reaction came to temperature. The reaction was stirred for 5 h at 84° C. The reaction was cooled to rt overnight, diluted with 75 mL saturated sodium bicarbonate, and stirred for 10 minutes. The slurry was filtered through a bed of Celite® diatomaceous earth and the filter pad was washed with fresh dichloromethane.
  • the white foam was dissolved in 10 mL absolute ethanol (EtOH) and was stirred for 2 h at rt as a fine white solid crystallized from the mixture. The solid was collected, washed with a small amount of EtOH, and dried on the filter to give 630 mg (9%) of pure C-1 alpha anomer as a white solid. The mother liquor was concentrated in vacuo to give 2.07 grams (32%) of the title compound 12 as a white foam (>20:1 C-1 Beta anomer). This material was used without additional fractionation.
  • the solution was treated with tetra-n-butylammonium fluoride on silica gel (21.16 g, 29.1 mmol) and was stirred at rt for 1 h.
  • the reaction mixture was treated with 18 g silica gel (230-400 mesh) and concentrated to dryness.
  • the solid plug was chromatographed over a 50 gram UltraSil® SNAP® cartridge while eluting with a 0-12.5% (10% MeOH in IPA)/dichloromethane gradient (0-50% of a 25% (10% MeOH in IPA)/dichloromethane polar phase) into 27 mL fractions on a Biotage® system.
  • the solid was triturated with 20 mL absolute EtOH for 1 h and the white solid was collected, washed with MeOH followed by diethyl ether and was dried on the filter overnight to afford 2.40 g (55%) of the title compound (1) as a fine white solid.
  • the mother liquor was concentrated in vacuo to give 2.05 g of a white foam that appeared to contain primarily the decomposition product of the title compound by TLC and LCMS. This residue was dissolved in MeOH, was treated with 10 mL Florisil® adsorbent (60-100 mesh, Sigma Aldrich), and was concentrated to dryness.
  • the plug was chromatographed over a 25 G UltraSil® SNAP® cartridge, eluting with a 5-25% MeOH/DCM gradient into 27 mL fractions. Fractions 15-22 were combined and concentrated to give 360 mg of a white foam. Crystallization of the foam from MeCN afforded an additional 264 mg (6%) of the title compound (1) as a fine white solid.
  • Embodiments of the disclosed compounds may be screened for anticancer activity using the NCI60 human tumor cell line anticancer drug screen (see, e.g., Shoemaker, Nature Reviews Cancer 2006, 6:813-823; https://dtp.cancer.gov/discovery_development/nci-60/handling.htm).
  • NCI60 testing is performed in two parts: first a single concentration is tested in all 60 cell lines at a single dose of 10 ⁇ 5 molar or 15 ⁇ g/ml. If the results obtained meet selection criteria, then the compound is tested again in all 60 cell lines in 5 ⁇ 10 fold dilutions with the top dose being 10 ⁇ 4 molar or 150 ⁇ g/ml. Compounds accepted for NCI60 testing are prepared for both 1-dose and 5-dose testing at the same time.
  • Agents Received Synthetics and pure compounds with known molecular weight and macromolecules and compounds without molecular weights—Aliquots of agents identified for testing are weighed and transferred into pre-weighed glass vials. Compounds are solubilized in these vials. Except when specifically noted, all agents are stored in a ⁇ 70° C. freezer. Crude Natural Products—crude natural product extracts are plated on detachable polypropylene (PP) 96-well microtiter plates. Plates are dried and stored at ⁇ 20° C. until called up for 1-dose testing.
  • PP polypropylene
  • those samples selected for 5-dose testing are rearranged from 88 wells to 72 wells per 96 well plate with a column of standard agent, Adriamycin, NSC 123127, and a new platemap is created and uploaded for assignment. Extracts are then solubilized at 40 mg/ml in DMSO or water.
  • Synthetic agents (macromolecules) without a molecular weight are prepared in DMSO:glycerol 9:1 (unless otherwise noted) at a concentration of 6 and 60 mg/ml which is diluted 1:400, giving a High Test concentration of 15 and 150 ⁇ g/ml.
  • Natural products crude extracts which are organic solvent soluble are prepared in DMSO, while those which were produced by aqueous extraction are solubilized in water, both at 40 mg/ml.
  • Special instructions (e.g. oxygen sensitive, light sensitive) can change the handling of the agent according to the instructions.
  • Fresh Compounds Compounds that are identified as needing to be prepared fresh before use are solubilized no more than one hour before serial dilution. It is serial diluted on a TECAN Freedom 200 (two drugs/plate), transferred to a column plate and stored under nitrogen in a desiccator box until delivered to the testing lab.
  • a shiplist is loaded into TECAN software which looks up quantity and MW (from DIS Oracle tables) and calculates volume of solvent to be added to each vial to get constant concentration (40 mM or 60,000 ⁇ g/ml) and adjusts concentrations if insufficient material for 1-dose and a test & one retest (75 ⁇ l @ 4 mM & 200 ⁇ l @ 40 mM+20% or 75 ⁇ l @ 6,000 ⁇ g/ml & 200 ⁇ l @ 60,000 ⁇ g/ml+20%).
  • a Platemap (defines which compound is in which well) for prescreen is uploaded via ORADIS to ORACLE PLATEWELL table.
  • Vials are put on the TECAN table in shiplist order as designated on the PLATEMAP printout.
  • TECAN Freedom robot adds appropriate volume of solvent (methanol/ethyl acetate/methyl-t-butyl ether, 6:3:1) to each vial to give constant concentration.
  • Technician inspects each vial individually and sonicates, warms, etc. to achieve solution keeping the time of exposure less than two hours.
  • Plate Preparation prior to drug solution transfer Technician prepares three 96 well PP detachable well plates (one for 1-dose and two for 60 cell testing): 100 ⁇ l of 10% glycerol in isopropanol is added to each well.
  • TECAN mixes drug solution in vial once then transfers 40 ⁇ L (400 ⁇ M) of drug solution into each well of the 96 well detachable plate for 1-dose and 400 ⁇ L (4,000 ⁇ M) into 96 well PP detachable well plates for full 60 cell screen. All plates are transferred to the SpeedVac system for drying. All solvent is removed by high vacuum without heating leaving a residue of glycerol plus drug in bottom of the well. Dry plates are stored @ ⁇ 70° C. until called for test, typically 1-3 weeks. Untransferred residue in glass vials is dried in a SpeedVac and stored dry at ⁇ 70° C. and can be used if additional retesting is required.
  • a strip of standards (adriamycin, NSC 123127 prepared and stored the same as the compounds) is added to the detachable well plate, and 90 ⁇ l DMSO is added to each well (4 mM solution), and mixed/sonicated and 75 ⁇ l is transferred, using a 12 channel hand pipettor, to a 12 channel reservoir plates (column plates), which is sealed and stored under nitrogen in a desiccator box until delivered to testing lab.
  • the labels are placed at the right and the left of the front of the reservoir plate. It will be the first and the last NSC number in the row. Rows are transferred from detachable plate to columns 3-12 of column plates. Plates are sealed and stored under nitrogen no more than 24 hours prior to drug addition.
  • the goal of solubilization is to deliver the highest requested concentration of an agent for the screening process. However, the number of vials required by the program screening the agent determines the minimum amount of vehicle that can be added. If the amount of material is insufficient to create the required number of aliquots, the concentration is dropped to ensure an appropriate volume is met.
  • Solubility Codes The agents will not always solubilize to a clear solution absent of particles. Therefore the solution is described via a code best describing the solubility of the agent in the vehicle. It is the clarity of the solution that is being evaluated. Presence or absence of color is not accounted for in the solubility codes.
  • the One-dose data will be reported as a mean graph of the percent growth of treated cells and will be similar in appearance to mean graphs from the 5-dose assay.
  • the number reported for the One-dose assay is growth relative to the no-drug control, and relative to the time zero number of cells. This allows detection of both growth inhibition (values between 0 and 100) and lethality (values less than 0). This is the same as for the 5-dose assay, described below. For example, a value of 100 means no growth inhibition. A value of 40 would mean 60% growth inhibition. A value of 0 means no net growth over the course of the experiment. A value of ⁇ 40 would mean 40% lethality. A value of ⁇ 100 means all cells are dead. Information from the One-dose mean graph is available for COMPARE analysis.
  • the human tumor cell lines of the cancer screening panel are grown in RPMI 1640 medium containing 5% fetal bovine serum and 2 mM L-glutamine.
  • RPMI 1640 medium containing 5% fetal bovine serum and 2 mM L-glutamine.
  • cells are inoculated into 96 well microtiter plates in 100 ⁇ L at plating densities ranging from 5,000 to 40,000 cells/well depending on the doubling time of individual cell lines. After cell inoculation, the microtiter plates are incubated at 37° C., 5% CO2, 95% air and 100% relative humidity for 24 h prior to addition of experimental drugs.
  • the plates are incubated for an additional 48 h at 37° C., 5% CO2, 95% air, and 100% relative humidity.
  • the assay is terminated by the addition of cold TCA.
  • Cells are fixed in situ by the gentle addition of 50 ⁇ L of cold 50% (w/v) TCA (final concentration, 10% TCA) and incubated for 60 minutes at 4° C. The supernatant is discarded, and the plates are washed five times with tap water and air dried.
  • Sulforhodamine B (SRB) solution 100 ⁇ L) at 0.4% (w/v) in 1% acetic acid is added to each well, and plates are incubated for 10 minutes at room temperature.
  • FIGS. 3A-3B show GI50 data for Compound 1 (4-amino-1-42R,3S,4S,5R)-3-fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrothiophen-2-yl)-1,3,5-triazin-2(1H)-one) and 5-aza-T-dCyd, respectively, against leukemia cell lines.
  • FIGS. 4A and 4B show GI50 data for Compound 1 and 5-aza-T-dCyd, respectively, against central nervous system (CNS) cancer cell lines.
  • FIGS. 5A and 5B show GI50 data for Compound 1 and 5-aza-T-dCyd, respectively, against renal cancer cell lines.
  • FIGS. 6A and 6B show GI50 data for Compound 1 and 5-aza-T-dCyd, respectively, against non-small cell lung cancer cell lines.
  • FIGS. 7A and 7B show GI50 data for Compound 1 and 5-aza-T-dCyd, respectively, against melanoma cell lines.
  • FIGS. 8A and 8B show GI50 data for Compound 1 and 5-aza-T-dCyd, respectively, against prostate cancer cell lines.
  • FIGS. 9A and 9B show GI50 data for Compound 1 and 5-aza-T-dCyd, respectively, against colon cancer cell lines.
  • FIGS. 10A and 10B show GI50 data for Compound 1 and 5-aza-T-dCyd, respectively, against ovarian cancer cell lines.
  • FIGS. 11A and 11B show GI50 data for Compound 1 and 5-aza-T-dCyd, respectively, against breast cancer cell lines.
  • Xenograft studies were performed in mice with tumors of HCT-116 human colon carcinoma cells, BL0382 human bladder carcinoma cells, OVCAR3 human ovarian carcinoma cells, NCI-H23 NSCLC human lung carcinoma cells, and HL-60 human leukemia cells.
  • Human tumor xenografts were generated in 4- to 6-week-old female athymic nude mice (nu/nu NCr) or NSG mice by subcutaneous injection of tumor cells (HL-60, NCI-H23, OVCAR-3, HCT-116) grown in vitro using RPMI 1640 with 10% fetal bovine serum and 2 mM 1-glutamine.
  • PDX patient-derived xenograft
  • BL0382F1232 tumor fragments were serially passaged from donor mice as described for other xenograft models (Plowman et al., “Human tumor xenograft models in NCI drug development.” In: Teicher, B. A. (Ed.), Anticancer Drug Development Guide: Preclinical Screening, Clinical Trials and Approval . Humana Press, Totowa, N.J., pp. 101-125; 1997).
  • the PDX donor tumors were produced by implantation of tumor material received from human patients into NSG mice.
  • mice were serially passaged in NSG mice and fragments were cryopreserved for subsequent establishment of newly tumored animals from the archived material.
  • the mice were housed in an AAALACi (Association for Assessment and Accreditation of Laboratory Animal Care International) accredited facility with food and water provided ad libitum.
  • AAALACi Association for Assessment and Accreditation of Laboratory Animal Care International
  • Groups included a vehicle control group as well as the drug-treated groups. Drug doses were selected based upon prior experience or newly conducted mouse tolerability studies as described elsewhere (ibid.).
  • the drug dosing was as follows:
  • FIGS. 12A and 12B Serial measurements of tumor volume and body weight were obtained post tumor implant. The results are shown in FIGS. 12A and 12B (HCT-116 human colon carcinoma cells), 13 A and 13 B (BL0382 human bladder carcinoma cells), 14 A and 14 B (OVCAR3 human ovarian carcinoma cells), 15 A and 15 B (NCI-H23 NSCLC human lung carcinoma cells), and 16 A and 16 B (HL-60 human leukemia cells).
  • a subject having, or suspected of having a disease, that may be treated with a halogenated 5-aza-T-dCyd analog is identified.
  • the disease may be a disease characterized at least in part by the presence of neoplastic cells.
  • the disease is a cancer.
  • the subject may be selected based on a clinical presentation and/or by performing tests to demonstrate presence of a disease, such as a cancer, characterized at least in part by presence of neoplastic cells.
  • the subject may have a solid tumor or a blood cancer.
  • the subject is treated by administering a halogenated 5-aza-T-dCyd analog, or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof at a dose determined by a clinician to be therapeutically effective.
  • the compound is 4-amino-1-((2R,3S,4S,5R)-3-fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrothiophen-2-yl)-1,3,5-triazin-2(1H)-one.
  • the compound is administered by any suitable means, such as parenteral (e.g., intravenous, intra-arterial, subcutaneous, intramuscular) or intrathecal injection or by oral administration.
  • Treatment efficacy may be assessed by conventional means, e.g., prevention of tumor growth, reduction in tumor growth, reduction in or lack of metastasis, normalization of blood cell counts, and the like.
  • assessment is performed by computed tomography (CT), magnetic resonance imaging (MRI), or positron emission tomography (PET) scans.
  • CT computed tomography
  • MRI magnetic resonance imaging
  • PET positron emission tomography
  • a therapeutically effective amount of a second active agent may be co-administered with the compound.
  • the compound and the second active agent may be administered either separately or together in a single composition.
  • the second active agent may be administered by the same route or a different route. If administered concurrently, the compound and the second active agent may be combined in a single pharmaceutical composition or may be administered concurrently as two pharmaceutical compositions.
  • the second active agent may be, for example, an anti-cancer agent, an anti-inflammatory agent, an antimicrobial agent, an antiviral agent, an anesthetic agent, or the like.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
US17/278,625 2018-09-25 2019-09-23 2'-halogenated-4'-thio-2'-deoxy-5-azacytidine analogs and use thereof Abandoned US20220033387A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US17/278,625 US20220033387A1 (en) 2018-09-25 2019-09-23 2'-halogenated-4'-thio-2'-deoxy-5-azacytidine analogs and use thereof

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862736246P 2018-09-25 2018-09-25
US17/278,625 US20220033387A1 (en) 2018-09-25 2019-09-23 2'-halogenated-4'-thio-2'-deoxy-5-azacytidine analogs and use thereof
PCT/US2019/052410 WO2020068657A1 (en) 2018-09-25 2019-09-23 2'-halogenated-4'-thio-2'-deoxy-5-azacytidine analogs and use thereof

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2019/052410 A-371-Of-International WO2020068657A1 (en) 2018-09-25 2019-09-23 2'-halogenated-4'-thio-2'-deoxy-5-azacytidine analogs and use thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US17/343,350 Continuation US11254662B2 (en) 2018-09-25 2021-06-09 2′-halogenated-4′-thio-2′-deoxy-5-azacytidine analogs and use thereof

Publications (1)

Publication Number Publication Date
US20220033387A1 true US20220033387A1 (en) 2022-02-03

Family

ID=68136598

Family Applications (2)

Application Number Title Priority Date Filing Date
US17/278,625 Abandoned US20220033387A1 (en) 2018-09-25 2019-09-23 2'-halogenated-4'-thio-2'-deoxy-5-azacytidine analogs and use thereof
US17/343,350 Expired - Fee Related US11254662B2 (en) 2018-09-25 2021-06-09 2′-halogenated-4′-thio-2′-deoxy-5-azacytidine analogs and use thereof

Family Applications After (1)

Application Number Title Priority Date Filing Date
US17/343,350 Expired - Fee Related US11254662B2 (en) 2018-09-25 2021-06-09 2′-halogenated-4′-thio-2′-deoxy-5-azacytidine analogs and use thereof

Country Status (7)

Country Link
US (2) US20220033387A1 (https=)
EP (1) EP3856754A1 (https=)
JP (1) JP7520822B2 (https=)
CN (1) CN112888698A (https=)
AU (1) AU2019349424B2 (https=)
CA (1) CA3110224A1 (https=)
WO (1) WO2020068657A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7520822B2 (ja) * 2018-09-25 2024-07-23 ザ ユナイテッド ステイツ オブ アメリカ， アズ リプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ ２’－ハロゲン化－４’－チオ－２’－デオキシ－５－アザシチジンアナログおよびその使用
EP4138843A4 (en) * 2020-04-23 2024-07-10 Southern Research Institute COMPOSITION FOR THE TREATMENT OF BLOOD CANCER USING 4'-THIO-5-AZA-2'-DEOXYCYTIDINE AND USES THEREOF
CN114644668B (zh) * 2020-12-18 2026-04-14 鲁南制药集团股份有限公司 一种合成地西他滨的方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11254662B2 (en) * 2018-09-25 2022-02-22 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services 2′-halogenated-4′-thio-2′-deoxy-5-azacytidine analogs and use thereof

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4675189A (en) 1980-11-18 1987-06-23 Syntex (U.S.A.) Inc. Microencapsulation of water soluble active polypeptides
JPS60100516A (ja) 1983-11-04 1985-06-04 Takeda Chem Ind Ltd 徐放型マイクロカプセルの製造法
CA1256638A (en) 1984-07-06 1989-06-27 Motoaki Tanaka Polymer and its production
JP2551756B2 (ja) 1985-05-07 1996-11-06 武田薬品工業株式会社 ポリオキシカルボン酸エステルおよびその製造法
DK0841344T3 (da) * 1996-04-09 2002-12-23 Yamasa Corp 1-(2-Desoxy-2-fluor-4-thio-Beta-D-arabinofuranosyl)cytosiner
ES2565929T3 (es) * 2004-10-25 2016-04-07 Dekk-Tec, Inc. Sales de mostaza de isofosforamida y análogos de las mismas como agentes antitumorales
US20060128654A1 (en) 2004-12-10 2006-06-15 Chunlin Tang Pharmaceutical formulation of cytidine analogs and derivatives
US7700567B2 (en) * 2005-09-29 2010-04-20 Supergen, Inc. Oligonucleotide analogues incorporating 5-aza-cytosine therein
JP5616968B2 (ja) 2009-12-18 2014-10-29 株式会社リブラメディシーナ 置換された１−Ｏ−アシル−２−デオキシ−２−フルオロ−４−チオ−β−Ｄ−アラビノフラノース類の製造方法
AU2013241341B2 (en) 2012-03-28 2016-09-08 Fujifilm Corporation Salt of 1-(2-deoxy-2-fluoro-4-thio-beta-D-arabinofuranosyl)cytosine
DK2883866T3 (da) 2012-08-13 2019-05-13 Fujifilm Corp MELLEMPRODUKT TIL SYNTESE AF 1-(2-DEOXY-2-FLUOR-4-THIO-beta-D- ARABINOFURANOSYL)CYTOSIN, MELLEMPRODUKT TIL SYNTESE AF THIONUKLEOSID OG FREMGANGSMÅDER TIL FREMSTILLING AF DISSE MELLEMPRODUKTER
CN103626765B (zh) * 2012-08-27 2016-08-10 广东东阳光药业有限公司 取代的氮杂吲哚化合物及其盐、组合物和用途
WO2015125781A1 (ja) 2014-02-18 2015-08-27 富士フイルム株式会社 チオラン骨格型糖化合物の製造方法およびチオラン骨格型糖化合物
JP6450356B2 (ja) 2016-02-29 2019-01-09 富士フイルム株式会社 液状医薬製剤
JP7425734B2 (ja) 2018-02-01 2024-01-31 ザ ユナイテッド ステイツ オブ アメリカ， アズ リプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ ２’－デオキシヌクレオシドを製造するための立体選択的合成およびプロセス

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11254662B2 (en) * 2018-09-25 2022-02-22 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services 2′-halogenated-4′-thio-2′-deoxy-5-azacytidine analogs and use thereof

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
"Routes of Administration", FDA, 11/14/2017 (Year: 2017) *
Advani et al., "A Phase II trial of gemcitabine and mitoxantrone for patients with acute myeloid leukemia in first relapse", Clin Lymphoma Myeloma Leuk., 2010 Dec (Year: 2010) *
American Chemical Society. Chemical Abstract Service. RN 169514-76-5, entered November 1, 1995 (Year: 1995) *
Bozhok et al., "Synthesis, Hydrolytic stability, and Antileukemic Activity of Azacytidine Nucleoside Analogs", Pharmaceutical Chemistry Journal, Vol 49, March 2016 (Year: 2016) *
Richard B. Silverman, "The Organic Chemistry of Drug Design and Drug Action", 2nd ed., Elsevier, 2004 (Year: 2004) *
Steiner et al., "Sulfur-Containing Glycomimetics". In: Fraser-Reid, B.O., Tatsuta, K., Thiem, J. (eds) Glycoscience. Springer, Berlin, Heidelberg (2008) (Year: 2008) *

Also Published As

Publication number Publication date
EP3856754A1 (en) 2021-08-04
JP2022502378A (ja) 2022-01-11
AU2019349424B2 (en) 2024-04-04
CA3110224A1 (en) 2020-04-02
US11254662B2 (en) 2022-02-22
CN112888698A (zh) 2021-06-01
JP7520822B2 (ja) 2024-07-23
WO2020068657A8 (en) 2021-03-18
AU2019349424A1 (en) 2021-03-18
US20210292310A1 (en) 2021-09-23
WO2020068657A1 (en) 2020-04-02

Similar Documents

Publication Publication Date Title
JP7582694B2 (ja) Ｍｅｋ阻害剤及びその治療的使用
US11254662B2 (en) 2′-halogenated-4′-thio-2′-deoxy-5-azacytidine analogs and use thereof
CN109152933B (zh) 诱导抗细胞凋亡bcl-2家族蛋白的降解的化合物及其用途
US20140073643A1 (en) Treatment of jak2-mediated conditions
US8212033B2 (en) Use of substituted quinazoline compounds in treating angiogenesis-related diseases
JP5738292B2 (ja) Ｊａｋ経路の阻害のための組成物および方法
JPH05506854A (ja) 局部活性眼用チアジアゾールスルホンアミドカルボニックアンヒドラーゼ抑制剤
ES2695302T3 (es) Novedosos inhibidores de DGAT2
JP2016538281A (ja) 血液脳関門を通過するタンパク質ホスファターゼ阻害剤
EA019289B1 (ru) Производные аминопиридина, аминопиримидина и амино-1,3,5-триазина
EA037517B1 (ru) Антипролиферативные соединения и их фармацевтические композиции и применения
JP2014514337A (ja) 多発性骨髄腫治療
US20200297696A1 (en) P38 inhibitors for the treatment of fshd
US20250179057A1 (en) Mek immune oncology inhibitors and therapeutic uses thereof
ES2967929T3 (es) Métodos de tratamiento de neoplasias hematológicas mediante 2-(2,6-dioxopiperidin-3-il)-4-((2-fluoro-4-((3-morfolinoazetidin-1-il)metil)bencil)amino)isoindolina-1,3-diona
JP2020518649A5 (https=)
EP0391971A1 (en) IMPROVED TOXICITY CURVES IN CHEMOTHERAPY.
JP2010520236A (ja) リソフィリンアナログとその使用法
US6251898B1 (en) Medical use of fluorenone derivatives for treating and preventing brain and spinal injury
DE69519581T2 (de) Guanidylmethyl cyclohexancarbonsäure ester derivate
US11464772B2 (en) Methods of treating acute or chronic pain
RU2812929C1 (ru) Ингибиторы mek и их терапевтическое применение
US20130217778A1 (en) Methods and compositions for the improvement of skeletal muscle function in a mammal
CN115073442B (zh) 含双硫键化合物、及其制法和药物组合物与用途
JPS6337787B2 (https=)

Legal Events

Date Code Title Description
AS Assignment

Owner name: THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES, MARYLAND

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:MORRIS, JOEL;WISHKA, DONN G.;LOPEZ, OMAR DIEGO;REEL/FRAME:055676/0306

Effective date: 20190925

STPP Information on status: patent application and granting procedure in general

Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER

STPP Information on status: patent application and granting procedure in general

Free format text: FINAL REJECTION MAILED

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION